Utilization of physiologically‐based pharmacokinetic model to assess disease‐mediated therapeutic protein‐disease‐drug interaction in immune‐mediated inflammatory diseases

It is known that interleukin‐6 (IL‐6) can significantly modulate some key drug‐metabolizing enzymes, such as phase I cytochrome P450s (CYPs). In this study, a physiologically‐based pharmacokinetic (PBPK) model was developed to assess CYPs mediated therapeutic protein drug interactions (TP‐DIs) in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lujing, Chen, Yang, Zhou, Wangda, Miao, Xin, Zhou, Honghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841519/
https://www.ncbi.nlm.nih.gov/pubmed/34581012
http://dx.doi.org/10.1111/cts.13164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841519/
https://www.ncbi.nlm.nih.gov/pubmed/34581012
http://dx.doi.org/10.1111/cts.13164

Ejemplares similares